Condensed title: EHZF, an early hematopoietic zinc finger protein. 
Introduction
The availability of reliable methods for the analysis of the gene expression profile in small populations of cells has enabled, in the recent past, the search for genes selectively expressed in hematopoietic stem and progenitor cells and potentially implicated in regulating the maintenance of the immature compartment of the hematopoietic system (1) (2) (3) (4) (5) (6) .
In this paper subtractive amplification has been used to highlight genes selectively expressed in human CD34 + cells, but not in peripheral blood mononuclear cells. One of the genes identified was further characterised as its predicted product displayed the structural features of a multifunctional transcription co-factor.
Homology studies revealed that this gene shares almost complete amino acid identity with Evi3, a gene identified as the retroviral integration site in murine AKXD-27 B cell lymphomas (7) . It was reported that following 3' LTR promoter insertion this gene was over expressed in B cell lymphomas, thus suggesting a role in the development or maintenance of these neoplasias. EHZF and Evi3 also display high homology both at the nucleotide and at the amino acid level to the olfactory associated zinc finger protein (OAZ) (8) (9) (10) , a kruppel-like 30 zinc finger co-transcription factor also referred to as early B-cell associated zinc finger protein (EBFAZ). This factor, originally identified for its ability to bind the Olf1/EBF transcription factor (9) , was subsequently implicated in the regulation of bone morphogenic protein (BMP)-responsive genes (8) . However, it is not known whether Evi3 is able to modulate EBF activity and/or BMP-dependent signalling.
Furthermore, the expression of murine Evi3 has been reported in B-cells at various stages of differentiation (7), but not analyzed in immature hematopoietic cells.
Since the human EHZF mRNA appeared to be abundant in early hematopoietic progenitors but not in mature blood cells, and considering the possible importance of this factor in human hematopoiesis and leukemogenesis, we studied -and report here -its expression in normal and malignant hematopoietic cells and its functional role in the control of BMP-and EBF-dependent pathways.
Methods

Cells and Cell lines. Hematopoietic progenitor cells (CD34 +
were isolated from peripheral blood of patients treated with human recombinant GM-CSF using the miniMACS system QBEND/10 Milteny (Biotech GMbH, Milan, Italy). The cells, >98%
For personal use only. on . by guest www.bloodjournal.org From positive for CD34 as assessed by flow cytometry, were cultured in Iscove's modified Dulbecco's medium containing 20% fetal calf serum (Flow, Milan Italy) and stimulated with GM-CSF (50U/ml), interleukin 3 (25U/ml) and EPO (2U/ml) (Boehringer-Mannheim, Milan, Italy). Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque (Pharmacia; Milan, Italy) density gradients. Cell lines, K-562, HEL, HPB-ALL, Jurkat, Molt-4, H9, IM9, Raji, Daudi, KG-1, THP-1, HL-60, U266, U-937 and MO7 were cultured in RPMI and 10% fetal calf serum. Hela, 293, CaCo2, 5637 and Hep3B were grown in alpha DEM, 10% fetal calf serum. P19 cells were obtained from LGC-Promochem-ATCC and cultured according to instructions.
Plasmids BRE4x-Luc (Minimum essential BMP responsive region, 4 copies) and Flaghuman-Oaz (pFlag-KIAA0760-L/CS2) and pFlag-human-Oaz(zf1-13)/Cs2 are as described in (8) Representational differential analysis (RDA) was performed using Smart cDNA and the PCR-Select cDNA Subtraction Kit (Clontech, BD), with cDNA prepared from CD34 cells as the 'tester' sample and cDNA from PBMC as the 'driver' fraction. The selectively amplified differentially expressed sequences (RsaI fragments) were cloned into the pGEM-T easy vector (Promega, Milan Italy) and inserts were sequenced with the T7 primer and the T7 sequencing kit (Pharmacia; Milan Italy). The sequences obtained were used to screen nucleic acid databases with the FASTA and BLAST programs. Virtual
Northerns were used to confirm the differential expression. The full-length sequence for EHZF was obtained by screening the DNA datase for overlapping "est" sequences, 3' RACE (Invitrogen, Milan, Italy) and screening of a lambda-gt11 cDNA library from K562
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The full-length cDNA was assembled by exploiting the presence of unique restriction sites and sub-cloned into the p3xFLAG-CMV TM -7.1 expression vector (Sigma-Aldrich).
The construct obtained was sequenced on both strands by MWG-Biotech, Germany.
Northern blotting RNA was prepared using the TRIzol reagent (Invitrogen, Milan Italy) with the addition of 20µg of glycogen when small numbers of cells were processed.
Northern blotting was performed using the H-bond N membrane (Amersham-Pharmacia).
The tissue mRNA poly A + Northern blots were purchased from Clontech-BD and hybridized with the supplied ExpressHyb solution. Probes (2-4 x 10 7 cpm) were prepared as described (1) 
Results
Identification and cloning of EHZF
Representational differential analysis (RDA) was used to identify transcripts expressed in EHZF also displays strong homology (63.5%) with the human zinc finger transcription factor Oaz (8) and its rat homologue, Roaz (63.2%) (9) . The highest homology between EHZF and Oaz ( Figure 1A ) lies within most of the zinc fingers, whereas a lesser degree of homology is detected in the sequences between the fingers. Oaz has been described to contain several distinct functional domains, responsible for direct DNA binding, BRE For personal use only. on October 3, 2017. by guest www.bloodjournal.org From C. The first 80 amino acids of EHZF, which contain the N-terminal domain not present in Oaz were analyzed using the Blastp alignment Mview program (16) . The amino acids highlighted are those shared by multiple proteins.
Expression of EHZF in hematopoietic and non-hematopoietic cells.
EHZF For personal use only. on October 3, 2017. by guest www.bloodjournal.org From A. Flow-cytometric analysis of purified CD34 + cells tested with anti-CD34-FITC and anti-CD38-PE. B. Flow-cytometric analysis of purified CD34 + cells after 7 days of cytokine treatment (GM-CSF, IL3 and Epo) with anti-CD14-FITC and anti-CD34-PE antibodies. C. CD34
+ cells were treated with cytokines for 1, 2, 5 and 7 days and tested with anti-CD14-FITC and anti-CD34-PE antibodies. The percentage of cells positive for CD14 (closed squares) and for CD34 (open squares) is shown. D. Total RNA was prepared and analyzed by Northern blotting from peripheral blood leukocytes (10µg), purified CD34 + cells either untreated (5µg) or exposed to GM-CSF, IL3 and Epo for 1, 2, 5, or 7 days (5µg, of all). The Northern blot was first hybridized with an EHZF probe, washed and exposed for 7 days and subsequently re-hybridized with a GAPDH probe, washed and exposed for 20 hours. The down regulation of EHZF was apparent in two additional CD34 + differentiation time courses analyzed by semi quantitative PCR (not shown).
Northern blotting performed on a panel of mRNAs from human tissues revealed a basal expression in most tissues apart from peripheral blood cells (Figure 3) , and showed particularly high levels in brain and spleen. Oaz instead, was relatively poorly expressed in hematopoietic tissues and found at highest levels in skeletal muscle and brain as reported (8) . Northern Blots from Clontech, containing 5 µg of polyA+ mRNA from different human tissues were hybridized sequentially with probes for EHZF, (exposed for 5 days), Oaz (exposed for 10 days) and then actin (exposed for 24 hours). The migration of the major EHZF band corresponds to a size of approx. 5.5 Kb, consistent with that observed in CD34 + cells and hematopoietic cell lines.
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Amounts of EHZF mRNA were assessed by Northern blotting and by RT-PCR with specific primers using cDNA derived from 100ng of RNA. The quantity of product is indicated, when undetectable after 40 cycles of PCR as (-); when low (+), moderate (++), high (+++) or abundant (++++).
The highest amounts of EHZF transcripts were found in the erythro-myeloid cell lines For Lymphnode (LN) samples were from normal subjects and from HD02, HD04, HD06, HD09 and NHL02 patient samples only. The filter was then later stripped in 0.5% SDS by boiling and the hybridized with a random primerlabeled probe for EBF which bound only to the cDNAs from CD19+ B lymphocytes. Subsequent stripping and hybridization of the filter with ubiqutin probe confirmed the uniform presence of cDNA in the filter spots.
B. RT-PCR analysis of EHZF expression in Acute Myelogenous Leukemia (AML).
cDNA was amplified by PCR in duplicate from AML RNA samples with primers specific for EHZF for 40 cycles, or with GAPDH primers for 24 cycles. PCR products were analyzed by 1% agarose gels and ethidium bromide staining. As controls 1 ng of plasmids pFlag-CS2-Oaz(KIAA0760-L), p3xFlagCMV7.1-EHZF or buffer containing no plasmid (control) were amplified for 20 cycles.
In order to better understand the expression pattern for EHZF in normal and malignant human hematopoietic cells, a commercial blood disease profiling array (Clontech) was Hodgkin's lymphomas. The EHZF mRNA levels in lymph nodes of these patients were equivalent to, or lower than, those of normal lymph nodes. To extend this finding RT-PCR analysis was performed on an additional set of AML RNA samples. Figure 4b shows high EHZF expression in 7 out of 13 human AML, (one M0, three M1, two M4 and one M5).
Taken together, the above data show significant of EHZF in the majority (52%) of AML cases, with no apparent association with a specific F.A.B. subset.
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DNA-binding, interaction with Smads and modulation of BRE-dependent and EBFdependent transcription by EHZF.
Roaz/oaz has been observed to directly bind to the palindromic sequence GCACCCTTGGGTGC within the X2 RBS oligonucleotide (10) . Electrophoretic mobility shifts assays were carried out to establish whether EHZF could also bind to this oligonucleotide. As shown in Figure 5B , both Oaz and its N-terminal portion, including the zinc fingers 1-13, are able to form specific complexes with X2.RBS. However, no binding could be detected when EHZF or an equivalent N-terminal-EHZF construct (EHZF-N) were tested, thus indicating different specificities for the two proteins. 
A. Expression of recombinant OAZ, EHZF, and their N-terminal domains in 293 cells.
Nuclear extracts were prepared from 293 cells 48 hours after transfection with either p3xFlagCMV7.1 void vector (F), pFlagCS2-Oaz(KIAA0760-L), pFlagCS2-Oaz(Zf1-13), p3xFlagCMV7.1-EHZF and p3xFlagCMV7.1-EHZF-N-terminal (1-2000bp) . The extracts were analyzed by Western blotting with M2 anti-flag antibody followed by anti-mouse antibody conjugated to horse-radish peroxidase and ECL.
B. Lack of EHZF binding to the X2.RBS oligonucleotide.
The nuclear extracts were analyzed by EMSA using 1-13 lanes is likely to represent 1-13 aggregates. The shift present in the uncompeted EHZF and EHZF-N lanes presumably reflects aspecific binding, since it is abolished by all specific and aspecific competitors.
C. Biotinylated oligonucleotide precipitation assay for the detection of BRE-interacting proteins.
293 cells were transfected with the pFlagCS2-Oaz(KIAA0760-L) or p3xFlagCMV7.1-EHZF vectors and co-transfected, when indicated, with pCDNA3-Smad1-His tagged and pCDNA-Smad4-His. 36 hours after transfection the cells were treated with BMP4 (25ng/ml) in the presence of 0.5% serum for 16 hours. Cell extracts were prepared, incubated with BRE-biotinylated oligonucleotide and streptavidinmagnetic beads were used to "pull down" the proteins associated to the oligonucleotide. Western blotting was performed to identify input and "pulled down" proteins with an anti-his antibody (1: For personal use only. on October 3, 2017. by guest www.bloodjournal.org From the BMP responsive element was specific: no effect was observed using other reporter constructs ( Figure. P19 cells or 293 were transfected with a -galactosidase expression plasmid as an internal control, in addition to the luciferase reporter plasmids and plasmids containing the cDNA for the transcription factors indicated. After 18 hours the medium was changed and at 36 hours cells were stimulated with BMP2/4 or TGF-. 48 hours after transfection, extracts were prepared assayed for -galactosidase. Based on its levels, normalized amounts of extracts were assayed for luciferase activity. The results shown are the average of triplicates from at least two independent experiments. a). P19 cells were co-transfected with pBRE-Luc and either the control vector p3xFlagCMV7.1, pFlagCS2-Oaz(KIAA0760-L) or p3xFlagCMV7.1-EHZF for 36 hours and were then incubated with either 50ng/ml BMP2, 25ng/ml BMP4 or 5ng/ml TGF-for 16 hours in the presence of reduced serum concentration (8) . b). 293 and c). P19 cells were co-transfected with either the control vector alone, pFlagCS2-Oaz(KIAA0760-L) 500ng, p3xFlagCMV7.1-EHZF 500ng or pFlagCS2-Oaz(KIAA0760-L) 500ng with the addition of either: 1. (500ng), 2. (1µg), 3. (2µg), 4. (4µg) of p3xFlagCMV7.1-EHZF, for 36 hours and when indicated exposed to 25ng/ml BMP4 for 16 hours in 0.5% serum. Cell extracts were normalized forgalactosidase activity and assayed for luciferase activity.
For
-5 M); e) pARE-Luc, (with or without co-transfected pEF-flag-Mixer); f) pDE-Luc (with or without co-transfected pEF-Flag-Fast-1) for 36 hours and then when indicated treated with 5ng/ml TGF-in 0.5% serum for 16 hours.
Considering the high homology between EHZF and OAZ/Roaz in the region involved in Olf/EBF binding (zinc fingers 28-30), we tested the ability of EHZF to modulate EBF dependent transcription. EBF has been shown to interact with the promoters for genes encoding the Ig-associated alpha and beta chains of the pre-B and B cell receptors and the surrogate light chain of the pre-B-cell receptor (including those for B29 and lambda 5) necessary for B-cell differentiation (12) . As shown in Figure 7 , EHZF repressed in a dosedependent manner the EBF-induced transcription of both the B29 and lambda 5 promoter constructs. EHZF per se was unable to activate transcription from these promoters. This indicates that EHZF can inhibit EBF transcriptional activity and -similarly to Oaz -behave as a bi-functional transcription co-factor. 293 cells were transfected with a -galactosidase expression plasmid as an internal control, the luciferase reporter plasmids, human pB29-Luc and p 5-Luc, and either void vector (p3xFlagCMV7.1) or p3xFlagCMV7.1-EHZF (2µg), pCDNA3.EBF-6xmyc(2µg), pCDNA3.EBF-6xmyc (2µg) + p3xFlagCMV7.1-EHZF (1µg), pCDNA3.EBF-6xmyc (2µg) + p3xFlagCMV7.1-EHZF (2µg) or pCDNA3.EBF-6xmyc (2µg) + pFlagCS2-Oaz(KIAA0760-L) (2µg). 48 hours later, extracts were prepared assayed for -galactosidase, normalized and assayed for luciferase activity. The results shown are the average of triplicates from three independent experiments.
Discussion
Over the past few decades it has become increasingly evident that the concerted expression of specific repertoires of regulatory genes -among which many encode transcription factors -is essential to ensure the balance between the maintenance of the immature hematopoietic cell compartment and the continual supply of differentiated blood cells in response to the requirements of the organism.
In this paper we have reported the identification, cloning, and molecular characterization of the gene coding for a novel Kruppel-like zinc finger protein, EHZF, whose expression in the normal hematopoietic system appears to be restricted to CD34 + stem/progenitor cells. Sequence analysis has revealed 63% homology with the Oaz/ Roaz protein and 96% homology with the mouse Evi3 gene product. Taking into account this high degree of amino acid identity between Evi3 and EHZF and the similarity of the intron/exon arrangement, EHZF may be considered the human homologue of Evi3.
Evi3 has been identified because of its proximity to the retroviral integration site in AKXD-27 murine B-cell lymphomas where its overexpression is induced by the adjacent retroviral 3' LTR element (7) . Apart from its potential implication in the development of murine B-cell lymphomas, little is known about the biological properties of this factor. Oaz instead has been characterized quite extensively, and displays the features of a multifunctional signal transduction mediator and transcription co-factor. The properties so far identified for this protein -that are mediated by distinct sets of zinc-finger motifsinclude: i) intrinsic DNA-binding ability (10) , ii) the capacity to form complexes with Smad1 and Smad 4 and activate the transcription driven by BMP-2 and -4 responsive elements (BREs) (8, 17) , and iii) the ability to interact with the neural and hematopoietic transcription factor Olf1/EBF1, and inhibit its binding to DNA.
As shown in this paper, EHZF shares the last two functions with OAZ ( Figures 5C-6-7 ), whereas it is unable to bind to the GCACCCTTGGGTGC motif ( Figure 5B ). EHZF is highly expressed in brain, but -unlike OAZ -significant levels of transcript are present in organs and tissues that contain stem and progenitor cells, myeloid and/or lymphoid, (ie:
placenta, spleen, lymph nodes, thymus, bone marrow, and fetal liver) (Figure 3 ). Within the hematopoietic system, the mRNA for EHZF is abundant in CD34 + cells, but undetectable in mature peripheral blood leukocytes (Figures 2 and 4A -data not shown), and its levels rapidly decrease during the differentiation of CD34 + cells in response to hemopoietins ( Figure 2D ). Taken together, these data support the notion that this factor (19, 20) , as well as the proliferation of human repopulating stem cells (21) , and to induce hematopoietic differentiation of rhesus monkey and murine embryonic stem cells in vitro (22, 23) . In the embryonic development, downstream targets of BMP4 signalling include the genes encoding a number of transcription factors that control hematopoiesis such as GATA-1, GATA-2, SCL and EKLF (23 ,24) . The polarized expression of BMP4 in the aorta-gonad-mesonephros region of the human embryo suggests a direct role in the specification of human definitive hematopoietic cells from the embryonic mesoderm (25, 26) . Finally, BMP4 has proven instrumental in stimulating the generation of multiple blood lineages from a distinct population of human fetal hematopoietic progenitors residing in muscle and neural tissue (27) .
In adult or neonatal cells, several lines of evidence have delineated a role for BMPs in the control of hematopoiesis (21, (28) (29) (30) . In particular, Bathia et al. (28) Another intriguing functional feature shared by EHZF and OAZ is the ability to associate to the transcription factor Olf1/EBF1 and repress its transcriptional activity, as shown in Evi3, the mouse homologue to EHZF, has been implicated in the development of B-cell lymphomas but not of myeloid leukemias in AKXD mice (7) . This appears to some extent in contrast with the notion, supported by the evidence cited above, that inhibition of the EBF pathway in B-cell progenitors results in loss of their lymphoid features. However, it should be considered that the AKXD mice, a recombinant inbred strain derived from the crossing of AKR/J and DBA/2J mice, are prone to developing B-and T-cell lymphomas rather than myeloid leukemias (37) . It is conceivable that -within the context of the genetic background of this strain -over expression of Evi3, by inhibiting the physiological maturation of B-cell progenitors, may contribute to the development of B-cell lymphomas.
It would be of interest to test whether in vitro culture of these malignant cells over Using RT-PCR analysis, Warming et al (7) detected the presence of mEvi3 transcript in normal B-lymphoid progenitors and mature cells from murine fetal liver and bone marrow.
In our study, expression of human EHZF was detectable both by Northern blot and RT-PCR in purified human CD34 + and in a substantial fraction (52%) of the acute myelogenous leukemias tested as well as in some chronic myelogenous leukemias, but not in mature blood cells (Figures 3-4 , data not shown) nor in the B-cell lines tested with the sole exception of Raji (Table I) Figure 4A ). This is not sufficient to rule out the possibility that B-lymphoid malignancies may express the factor. The generation of antibodies to EHZF and immunohistochemistry studies will help clarify this issue. However, the mRNA analysis of human samples reported in this paper highlights a difference between the expression profile of EHZF and that of its murine counterpart: in the normal human hematopoietic system, the expression EHZF is restricted to immature blood cells, and relatively abundant levels of transcript are a common finding in AML cells.
The gene for EHZF is found on chromosome 18 at 18q11.2, this region 18q11-12 is frequently lost in human squamous colon and pancreatic cancers (38, 39) . It will be of interest to determine whether chomosomal alteration may be associated with the deregulation of expression of EHZF in AML leukemic samples.
In the light of the evidence present in the literature, the data reported in this paper delineate a potential role for human EHZF in the maintenance of the hematopoietic stem and progenitor cell compartment, and possibly in the pathogenesis of myeloid leukemias.
The modulation of EHZF expression in human CD34 + cells as well as in embryonic stem
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From cells will help gain further insight in the biological functions of this factor, and define its importance in the development and the homeostasis of the hematopoietic system.
